| Recruiting | The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER Metastatic Colorectal Cancer (mCRC) | Phase 2 | 2025-06-16 |
| Withdrawn | Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer CCR5, Microsatellite Stable, Metastatic | Phase 2 | 2022-09-20 |
| Completed | Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19 Coronavirus Disease 2019 | Phase 2 | 2021-03-01 |
| Completed | Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 2020-12-01 |
| Completed | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors Solid Tumor, Adult | Phase 2 | 2020-05-01 |
| Completed | Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19 Coronavirus Disease 2019 | Phase 2 | 2020-04-16 |
| Completed | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 Coronavirus Disease 2019 | Phase 2 | 2020-04-01 |
| Terminated | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | 2019-04-22 |
| Completed | PRO 140 in Treatment-Experienced HIV-1 Subjects HIV-1-infection | Phase 2 / Phase 3 | 2018-06-25 |
| Terminated | An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study HIV-1-infection | Phase 2 / Phase 3 | 2017-08-29 |
| Terminated | A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation Graft Vs Host Disease | Phase 2 | 2017-05-14 |
| Completed | Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 HIV | Phase 2 / Phase 3 | 2016-12-07 |
| Terminated | An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study Human Immunodeficiency Virus (HIV) | Phase 2 / Phase 3 | 2016-11-03 |
| Completed | Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140 HIV | Phase 2 / Phase 3 | 2015-10-01 |
| Terminated | An Extension of Protocol PRO 140_CD01 Study HIV, Human Immunodeficiency Virus | Phase 2 | 2014-11-18 |
| Completed | Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection HIV, Human Immunodeficiency Virus | Phase 2 | 2014-04-16 |
| Withdrawn | A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to HIV | Phase 2 | 2013-12-01 |
| Completed | Observational Study of Blood Treated With Cytolin HIV Infections | — | 2010-01-01 |
| Completed | Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection HIV -1 Infection, HIV Infections | Phase 2 | 2008-03-01 |
| Completed | PRO 140 by IV Administration in Adults With HIV-1 Infection HIV Infections | Phase 2 | 2007-12-01 |
| Completed | Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers HIV Infections | Phase 1 | 2004-04-16 |
| Available | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Pa TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer | — | — |
| No Longer Available | A Compassionate Use Study of Leronlimab in Breast Cancer Metastatic Triple-Negative Breast Carcinoma | — | — |
| No Longer Available | An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study HIV | — | — |